597 related articles for article (PubMed ID: 31016870)
21. Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups.
Mo XD; Xu LP; Zhang XH; Liu DH; Wang Y; Chen H; Yan CH; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Int J Cancer; 2015 Apr; 136(7):1697-707. PubMed ID: 25138425
[TBL] [Abstract][Full Text] [Related]
22. Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience.
Tekgündüz E; Göker H; Kaynar L; Sarı İ; Pala Ç; Doğu MH; Öztürk E; Turgut B; Korkmaz S; Tetik A; Büyükaşık Y; Hacıoğlu SK; Bozdağ SC; Özdemir E; Altuntaş F
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):269-74. PubMed ID: 26927932
[TBL] [Abstract][Full Text] [Related]
23. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China.
Gao L; Zhang C; Gao L; Liu Y; Su Y; Wang S; Li B; Yang T; Yuan Z; Zhang X
J Hematol Oncol; 2015 Jul; 8():90. PubMed ID: 26208715
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
[TBL] [Abstract][Full Text] [Related]
25. Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.
Chamseddine AN; Willekens C; De Botton S; Bourhis JH
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S129-40. PubMed ID: 26297265
[TBL] [Abstract][Full Text] [Related]
26. Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia.
Takashima S; Miyamoto T; Kamimura T; Yoshimoto G; Yoshida S; Henzan H; Takase K; Kato K; Ito Y; Ohno Y; Nagafuji K; Eto T; Techima T; Akashi K
Int J Hematol; 2015 Dec; 102(6):689-96. PubMed ID: 26475283
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Analysis of Dasatinib and Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia].
Li Y; Wang BJ; Liu W; Liang ZY; Yin Y; Dong YJ; Wang Q; Sun YH; Xu WL; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):18-23. PubMed ID: 32027247
[TBL] [Abstract][Full Text] [Related]
29. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang Y; Feng S
Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
[TBL] [Abstract][Full Text] [Related]
30. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
Short NJ; Kantarjian HM; Sasaki K; Ravandi F; Ko H; Cameron Yin C; Garcia-Manero G; Cortes JE; Garris R; O'Brien SM; Patel K; Khouri M; Thomas D; Jain N; Kadia TM; Daver NG; Benton CB; Issa GC; Konopleva M; Jabbour E
Am J Hematol; 2017 Mar; 92(3):238-243. PubMed ID: 28006851
[TBL] [Abstract][Full Text] [Related]
31. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
32. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
[TBL] [Abstract][Full Text] [Related]
34. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
Ram R; Storb R; Sandmaier BM; Maloney DG; Woolfrey A; Flowers ME; Maris MB; Laport GG; Chauncey TR; Lange T; Langston AA; Storer B; Georges GE
Haematologica; 2011 Aug; 96(8):1113-20. PubMed ID: 21508120
[TBL] [Abstract][Full Text] [Related]
35. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
Zeng Q; Xiang B; Liu Z
Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
[TBL] [Abstract][Full Text] [Related]
36. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
37. Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hara R; Onizuka M; Kikkawa E; Shiraiwa S; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Ogawa Y; Kawada H; Matsushita H; Ando K
Ann Hematol; 2021 Oct; 100(10):2479-2486. PubMed ID: 34247299
[TBL] [Abstract][Full Text] [Related]
38. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
Jabbour E; Haddad FG; Short NJ; Kantarjian H
JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lou Y; Ma Y; Li C; Suo S; Tong H; Qian W; Mai W; Meng H; Yu W; Mao L; Wei J; Xu W; Jin J
Front Med; 2017 Jun; 11(2):229-238. PubMed ID: 28349299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
